David Kim, PharmD
David Kim, PharmD
Dr. Kim, a graduate of the Massachusetts College of Pharmacy and Health Sciences - Boston, is a Pharmacy Officer in the United States Air Force (USAF). He is currently on military leave from Mayo Clinic (Rochester, MN) to serve his country. He is a peer-reviewer for the Iowa Pharmacy Association and holds APhA certifications such as Medication Therapy Management and Diabetes Care. The views expressed in his publications do not reflect the views of the Mayo Clinic, USAF, Department of Defense, or the United States Government.
Jan 11, 2019 @07:33 PM
Glucagon-like peptide-1 receptor agonists have been gaining popularity to treat diabetes. Does this one provide advantages over competitors?

Apr 26, 2018 @06:06 AM
Solanezumab did not significantly affect cognitive decline compared with the placebo in subjects with mild Alzheimer's, but there are still takeaways.

Apr 13, 2018 @07:56 PM
Pharmacists often encounter patients with Heparin-induced Thrombocytopenia (HIT) in health care settings. Here are some useful information in regards to HIT.

Feb 16, 2018 @02:00 PM
Tissue Plasminogen Activator (tPA) is administered in patients with Acute Ischemic Stroke. Becuase tPA administration is time sensitive, caution is required.

Dec 21, 2017 @04:25 AM
HMG-CoA reductase inhibitors are a class of lipid-lowering medications. Here is a look at guidelines and studies for health care professionals.

Nov 16, 2017 @02:29 AM
What role does this medication play in diabetes therapy, and what are its clinical benefits, compared with competitors?